https://www.selleckchem.com/pr....oducts/cwi1-2-hydroc
Decentralized, or distributed, manufacturing that takes place close to the point of care has been a manufacturing paradigm of heightened interest within the cell therapy domain because of the product's being living cell material as well as the need for a highly monitored and temperature-controlled supply chain that has the potential to benefit from close proximity between manufacturing and application. To compare the operational feasibility and cost implications of manufacturing autologous chimeric antigen receptor T (CAR T
Like
Comment
Share
